VYNEVYNE Therapeutics Inc
$0.6561
$0.009
(1.35%)
Closed $0.6561
$0.0251
(3.83%)
After Hours
Mkt Cap$22.18M
Vol51,048.00
Fundamentals
Mkt Cap
$22.18M
Volume
-
52W High
$1.96
52W Low
$0.2805
PE Ratio
-1.23
Avg. Volume
247,314.79
EPS (Annual)
-$0.6192
Rev/Employee
$57,000.00
Earnings
-
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE...
PR Newswire
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether VYNE...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE...
PR Newswire
Penny Stocks To Watch Now - December 17th
Direxion Daily TSLA Bear 1X Shares, Canopy Growth, VYNE Therapeutics, Better Choice, Rezolve AI, Bitfarms, and iRobot are the seven Penny stocks to watch today, according to MarketBeat's stock...
MarketBeat
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion...
Business Wire
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest VYNE News
ViewSHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN
PR Newswire
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
PR Newswire
Advertisement|Remove ads.